



6th Course in vivo Preclinical Assays in Cancer Therapy
 May 21-23 2014, Institut Curie, Paris, France



Wednesday 21 st May 2014		
09:00-09:35	Cancer cell line screening (1/2)	Yves POMMIER, CCR NCI, Bethesda, USA
09:35-10:10	Cancer cell line screening (2/2)	Mathew GARNETT, Sanger Institute, Hinxton, UK
10:30-11:00	<i>Coffee break</i>	
11:00-11:30	3D cancer models	Robert VRIES, Hubrecht Institute, Utrecht, NL
11:45-12:15	Ex vivo drug screening of PDX	Alejandra BRUNA, CRUK CI, Cambridge, UK
12:30-13:00	Zebrafish model	Marina MIONE, KIT, Karlsruhe, GE
<i>LUNCH</i>		
14:15-14:45	Genetically Engineered Mouse models / colorectal cancer	Sylvie ROBINE, Institut Curie, Paris, FR
15:00-15:20	Patient Derived Xenograft / colorectal cancer	Virginie DANGLES-MARIE, Institut Curie, Paris, FR
15:45-16:15	<i>Coffee break</i>	
16:15-16:45	GEM models / breast cancer	Martine VAN MILTENBURG, NKI, Amsterdam, NL
17:00-17:30	PDX models / breast cancer	Elisabetta MARANGONI, Institut Curie, Paris, FR
<i>Poster session & drinks</i>		

Thursday 22nd May 2014

09:00 - 09:30	Anatomopathological analysis of tumour animal models	Alexander BOROWSKY, UC Davis Comprehensive Cancer Center, Sacramento, USA
09:45-10:15	Angiogenesis targeting	Oriol CASANOVAS, IDIBELL, Barcelona, SP
10:30 - 10:50	Ethics and Animal Welfare	Sue ECCLES, ICR, Sutton, UK
11:00-11:30	<i>Coffee break</i>	
11:30-12:00	Metastasis studies	Sue ECCLES, ICR, Sutton, UK
12:15-12:45	PDX models of lung cancer	Massimo MORO, IRCCS, Milan, IT
	<i>LUNCH</i>	
14:00-14:30	Lung cancer in GEM	David SANTAMARIA, CNIO, Madrid, SP
14:45-15:15	Pancreas PDX	Manuel HIDALGO, CNIO, Madrid, SP
15:30-16:00	<i>Coffee break</i>	
16:00-16:40	Pediatric Preclinical testing program	Peter HOUGHTON, Nationwide Children's Hospital, Columbus, USA
16:50-17:10	European PDX consortium	Sergio ROMAN-ROMAN, Institut Curie, Paris, FR
17:20-18:00	Incorporating preclinical data in the setting of early phase clinical trials	Eric RAYMOND, CHUV, Lausanne, SZ

Social dinner

Friday 23rd May 2014

9:00 - 9:30	Metabolic biomarkers in preclinical studies	Siver MOESTUE, NTNU, Trondheim, NO
9:45 - 10:15	Chemoresistance in GEM models	Sven ROTTENBERG, NKI, Amsterdam, NL
10:15-10:45	<i>Coffee break</i>	
10:45-11:15	Resistance to targeted therapies in colorectal PDX	Livio TRUSOLINO, IRCC, Turino, IT
11:30 - 12:00	Immune system and chemotherapy response	Seth COFFELT, NKI, Amsterdam, NL

